Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,197,104 papers from all fields of science
Search
Sign In
Create Free Account
Ly-2127399
Known as:
LY2127399
, LY3022859
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
tabalumab
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors
A. Tolcher
,
J. Berlin
,
+10 authors
D. Hong
Cancer Chemotherapy and Pharmacology
2017
Corpus ID: 4788023
PurposeLY3022859 is an anti-TGFβRII IgG1 monoclonal antibody that inhibits receptor-mediated signaling activation. The primary…
Expand
2016
2016
Dose‐escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma
S. Iida
,
Daisuke Ogiya
,
+8 authors
K. Tobinai
Cancer Science
2016
Corpus ID: 14571075
B‐cell activating factor (BAFF) promotes the survival and adhesion of multiple myeloma (MM) cells. Tabalumab (LY2127399) is an…
Expand
Review
2015
Review
2015
Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents
A. Lenert
,
P. Lenert
Drug Design, Development and Therapy
2015
Corpus ID: 7571257
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) comprises several clinical entities with diverse clinical…
Expand
Review
2013
Review
2013
Treating multiple sclerosis with monoclonal antibodies: a 2013 update
Annika Deiß
,
I. Brecht
,
A. Haarmann
,
M. Buttmann
Expert Review of Neurotherapeutics
2013
Corpus ID: 169334
The third part of this in-depth review series on the treatment of multiple sclerosis (MS) with monoclonal antibodies covers the…
Expand
2013
2013
SAT0005 Human C-Type Lectin Domain Family 4, Member C Gene Expression Level Helps Predict Future Clinical Response to Tabalumab Blockade of Baff in Rheumatoid Arthritis
E. Dow
,
P. Banerjee
,
+6 authors
R. Hoffman
2013
Corpus ID: 76032492
Background Patients with rheumatoid arthritis (RA) exhibit substantial variability in both the magnitude and duration of their…
Expand
Review
2012
Review
2012
Biologic Differences Between Various Inhibitors of the BLyS/BAFF Pathway: Should We Expect Differences Between Belimumab and Other Inhibitors in Development?
W. Stohl
Current Rheumatology Reports
2012
Corpus ID: 42980394
For the first time in more than 50 years, the US Food and Drug Administration has approved a drug specifically for the treatment…
Expand
2011
2011
Phase I study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously treated multiple myeloma.
N. Raje
,
R. Hohl
,
+9 authors
K. Anderson
Journal of Clinical Oncology
2011
Corpus ID: 5681230
8012 Background: LY2127399 (LY) is a human mAb that neutralizes membrane-bound and soluble B cell activating factor (BAFF). LY…
Expand
Review
2011
Review
2011
Targeting Bone as a Therapy for Myeloma
Ping Wu
,
G. Morgan
Cancer Microenvironment
2011
Corpus ID: 5625933
Myeloma bone disease (BD) not only impairs quality of life, but is also associated with impaired survival. Studies of the biology…
Expand
Review
2010
Review
2010
Treating multiple sclerosis with monoclonal antibodies: a 2010 update
M. Buttmann
Expert Review of Neurotherapeutics
2010
Corpus ID: 24588796
Treating multiple sclerosis (MS) with monoclonal antibodies (mAbs) has been marked by both progress and setbacks in the past 2…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE